Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results.
FDA approved ZANVASTRO as the first disease-modifying therapy for Alexander disease, with a broad label for children and adults. Approval was based on clinical data showing motor function benefit and favorable safety.
ZANVASTRO received early FDA approval as the first disease-modifying therapy for Alexander disease, with a broad label for children and adults. The pivotal trial reported motor function stabilization and a favorable safety profile.